CLINICAL TRIAL article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1508918
The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy
Provisionally accepted
- 1Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University,, Nanjing, China
- 2Wuxi No.2 People's Hospital, Nanjing Medical University, Wuxi, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Aim: Patients on premixed insulin therapy usually have poor glycemic control. This study aimed to investigate the effect of vildagliptin in these patients. Methods: This real-world study included patients with type 2 diabetes mellitus (T2DM), who were poorly glycemic controlled on premixed insulin therapy and were subsequently added vildagliptin. The control group consisted of patients who only had their insulin doses adjusted without adding vildagliptin, matched for age, diabetic duration, HbA1c, and BMI. All patients underwent FGM, glycated hemoglobin(HbA1c), and glycated albumin(GA) measurements at baseline and three months after the treatment adjustment. Results: Patients receiving vildagliptin treatment demonstrated significant reductions in HbA1c and GA levels (P<0.001 and P=0.009, respectively). The vildagliptin group exhibited a remarkable decrease in the mean amplitude of glycemic excursion (MAGE) (8.58±0.36 vs. 6.62±0.47, P<0.001), along with notable reductions in mean blood glucose (MBG) (10.7±0.34 vs. 8.82±0.39, P<0.001) and time above the target range (TAR) (52.60±3.44 vs. 31.59±4.31, P<0.001) compared to the control group. Moreover, there were notable improvements in the duration spent within the target range (TIR) (45.64±3.33 vs. 64.22±4.00, P<0.001), along with increases in the areas under the curve (AUC) for blood glucose levels above 4. 4 (426.82±83.19 vs. 892.16± 185.27, P=0.018) and 3.9 (213.81±47.20 vs. 454.77±103.21, P=0.029). Hourly mean blood glucose levels over a 2-week period monitored by FGM indicated lower blood glucose levels in the vildagliptin group, particularly after dinner (P=0.022).Vildagliptin added to premixed insulin effectively lowers blood glucose levels and reduces glycemic variability in patients with type 2 diabetes mellitus. Clinical Trial Registration: https://clinicaltrials.gov/NCT04847219.
Keywords: vildagliptin, type 2 diabetes mellitus, Glycemic excursion, flash glucose monitoring, Premixed insulin
Received: 10 Oct 2024; Accepted: 04 Jun 2025.
Copyright: © 2025 Kong, Shen, Jiang, Xie, Yan, Jing, Hu and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yun Hu, Wuxi No.2 People's Hospital, Nanjing Medical University, Wuxi, Jiangsu Province, China
Jianhua Ma, Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University,, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.